Zusammenfassung
Subkutane Apomorphininjektionen sind eine wertvolle und effektive Therapie für Parkinson-Patienten
mit wiederholten „Off”-Phasen trotz optimierter peroraler Therapie. Die durchschnittliche
tägliche Zeit in „Off” kann damit halbiert werden, und die bestehen bleibenden „Off”-Perioden
sind weniger ausgeprägt. Diese Effekte sind stabil, auch über längere Zeit, und es
gibt keinen Anhalt für eine Toleranzentwicklung. Die Nebenwirkungen sind meistens
gering ausgeprägt. Beste Effekte werden erreicht, wenn Apomorphin bei relativ jungen,
aktiven und kognitiv gut funktionierenden Patienten eingesetzt wird. Subkutane Apomorphininjektionen
verbessern nicht selten die Möglichkeit weiterzuarbeiten und ein weitgehend normales
Leben zu führen. Durch diese zuverlässige Methode, schnell aus einer „Off”-Phase zu
kommen, führt die Therapie zu mehr Freiheitsgefühl und Selbstvertrauen bei den Betroffenen.
Abstract
Apomorphine as subcutaneous injections offers a valuable and effective treatment alternative
for Parkinson patients with oral medication-resistant „off” phases. Its efficacy is
stable during long-term therapy, with no signs of patient tolerance. Adverse events
are usually mild. The best results are obtained with relatively young, active, and
cognitively intact patients. Intermittent s. c. apomorphine therapy can improve the
patients' possibilities to continue to work and to live a normal social life, by offering
increased freedom and self-confidence through a reliable, quick rescue from the disabling
medication-resistant „off” phases.
Literatur
- 1
Pietz K, Hagell P, Odin P.
Subcutaneous apomorphine in late stage Parkinson's disease: A long-term follow-up.
J Neurol Neurosurg Psychiatry.
1998;
65
709-716
- 2
Hagell P, Odin P.
Apomorphine in the treatment of Parkinson's disease.
J Neurosci Nurs.
2001;
33
21-38
- 3
Poewe W, Kleedorfer B, Wagner M. et al .
Side-effects of subcutaneous apomorphine in Parkinson's disease.
Lancet.
1989;
i
1084-1085
- 4
Pollak P, Champay A S, Gaio J M. et al .
Administration sous-cutanée d'apomorphine dans les fluctuations motrices de la maladie
de Parkinson.
Rev Neurol (Paris).
1990;
146
116-122
- 5
Kempster P A, Iansek R, Larmour I.
Intermittent subcutaneous apomorphine injection treatment for Parkinson's disease.
Aust NZ J Med.
1991;
21
314-318
- 6
Hughes A J, Bishop S, Kleedorfer B. et al .
Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration
for up to five years.
Mov Disord.
1993;
8
165-170
- 7
Merello M, Leiguarda R.
Tratamiento de las fluctuationes motoras de la enfermedad de parkinson con inyecciones
subcutaneas de apomorfina.
Medicina (B Aires).
1995;
55
5-10
- 8
Esteban-Munoz J, Marti M J, Marin C, Tolosa E.
Long-term treatment with intermittent intranasal or subcutaneous apomorphine in patients
with levodopa-related motor fluctuations.
Clin Neuropharmacol.
1997;
20
245-252
- 9
Östergaard L, Werdelin L, Odin P. et al .
Pen injected apomorphine against off phenomena in late Parkinson's disease: a double
blind, placebo controlled study.
J Neurol Neurosurg Psychiatry.
1995;
58
681-687
- 10
Factor S A.
Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Neurology.
2004;
62
S12-S17
- 11
Dewey R B, Hutton T, LeWitt A, Factor S A.
A randomized, double-blind, placebo-controlled trial of subcutaneously injected Apomorphine
for parkinsonian off-state events.
Arch Neurol.
2001;
58
1385-1392
- 12
Duby S E, Cotzias G C, Papavasiliou P S, Lawrence W H.
Injected apomorphine and orally administered levodopa in parkinsonism.
Arch Neurol.
1972;
27
474-480
- 13
Victor J FS, Pollak P, Gervason C L, Perret J.
Levodopa-induced diphasic dyskinesia improved by subcutaneous apomorphine.
Mov Disord.
1992;
7
283-284
- 14
Frankel J P, Lees A J, Kemster P A, Stern G M.
Subcutaneous apomorphine in the treatment of Parkinson's disease.
J Neurol Neurosurg Psychiatry.
1990;
53
96-101
- 15
Factor S A, Brown D L, Molho E S.
Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's
disease.
Mov Disord.
2000;
15
167-169
- 16
Tison F, Wiart L, Guatterie M. et al .
Effects of central dopaminergic stimulation by apomorphine on swallowing disorders
in Parkinson's disease.
Mov Disord.
1996;
11
729-732
- 17
Edwards L L, Quigley E MM, Harned R K. et al .
Defecatory function in Parkinson's disease: response to apomorphine.
Ann Neurol.
1993;
33
490-493
- 18
Christmas T J, Kempster P A, Chapple C R. et al .
Role of subcutaneous apomorphine in Parkinsonian voiding dysfunction.
Lancet.
1988;
2
1451-1453
- 19
Laar T van, Jansen E N, Essink A W, Neef C.
Intranasal apomorphine in parkinsonian on-off fluctuations.
Arch Neurol.
1992;
49
482-484
- 20
Koller W, Stacy M.
Other formulations and future considerations for apomorphine for subcutaneous injection
therapy.
Neurology.
2004;
64, Suppl 4
S22-S26
- 21
Dewey Jr R B, Maraganore D M, Ahlskog J E, Matsumoto J Y.
Intranasal apomorphine rescue therapy for parkinsonian „off” periods.
Clin Neuropharmacol.
1996;
19
193-201
- 22
Kapoor R, Turjanski N, Frankel J. et al .
Intranasal apomorphine: a new treatment in Parkinson's disease.
J Neurol Neurosurg Psychiatry.
1990;
53
1015
- 23
Kleedorfer B, Turjanski N, Ryan R. et al .
Intranasal apomorphine in Parkinson's disease.
Neurology.
1991;
41
761-762
- 24
Wickremaratchi M, Hadjikoutis S, Lambert P. et al .
A tolerability study of intranasal apomorphine powder (5 mg) in subjects with Parkinson's
disease and motor fluctuations over a 7-day period: a phase two study.
Mov Disord.
2002;
17, suppl 5
S103-S104
- 25
Sam E, Jeanjean A P, Maloteaux J M, Verbeke N.
Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
Eur J Drug Metab Pharmacokinet.
1995;
20
27-33
- 26
Montastruc J L, Rascol O, Senard J M. et al .
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
Clin Neuropharmacol.
1991;
14
432-437
- 27
Ondo W, Hunter C, Almaguer M. et al .
Efficacy and tolerability of a novel sublingual apomorphine preparation in patients
with fluctuating Parkinson's disease.
Clin Neuropharmacol.
1999a;
22
1-4
- 28
Ondo W, Hunter C, Almaguer M, Jankovic J.
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's
disease.
Mov Disord.
1999b;
14
664-668
- 29
Hughes A J, Webster R, Boningdon M. et al .
Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor
fluctuations.
Clin Neuropharmacol.
1991;
14
556-561
Prof. Dr. med. Per Odin
Abt. Neurologie · Zentralkrankenhaus Reinkenheide
Postbrookstraße 103
27574 Bremerhaven
Email: per.odin@klinikum-bremerhaven.de
